Immunome (IMNM) Stock Price, News & Analysis

Company Overview

Immunome, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens. In parallel, Immunome is advancing additional candidates in solid tumors, including antibody–drug conjugates and immunomodulatory antibodies that aim to stimulate anti-tumor immune responses. Beyond oncology, the platform has been applied to infectious disease programs, where candidate antibodies against emerging viral threats have been identified and optimized for potential therapeutic or prophylactic use.

Founded in the early 2000s and headquartered in Ann Arbor, Michigan, Immunome has grown from a privately held research operation into a publicly traded company listed on the Nasdaq exchange under the ticker “IMNM.” In 2021, the company completed its initial public offering, providing capital to support ongoing clinical development and platform expansion. Led by President and Chief Executive Officer Greg Bailey, Immunome maintains collaborations with academic institutions and industry partners to advance its pipeline and explore new therapeutic applications of its discovery platform.

Key Stats

• Today's Range: $21.81 to $23.30
• 50-Day Range: $19.30 to $24.63
• 52-Week Range: $7.28 to $27.65
• Volume: 609,103 shs
• Average Volume: 860,907 shs
• Market Capitalization: $2.51 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.45
• Consensus Rating: Moderate Buy

Immunome Stock Analysis - MarketRank™

Immunome scored higher than 74% of companies evaluated by MarketBeat, and ranked 168th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Immunome has received a consensus rating of Moderate Buy. The company's average rating score is 2.91, and is based on 1 strong buy rating, 9 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Immunome has a consensus price target of $33.45, representing about 50.8% upside from its current price of $22.19.

Amount of Analyst Coverage

Immunome has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Immunome are expected to grow in the coming year, from ($2.50) to ($2.45) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Immunome is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Immunome is -9.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Immunome has a P/B Ratio of 3.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.81% of the float of Immunome has been sold short.

Short Interest Ratio / Days to Cover

Immunome has a short interest ratio ("days to cover") of 16.64, which indicates bearish sentiment.

Change versus previous month

Short interest in Immunome has recently decreased by 1.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Immunome does not currently pay a dividend.

Dividend Growth

Immunome does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.83

News Sentiment

Immunome has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Immunome this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for IMNM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added Immunome to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Immunome insiders have sold 13,657.14% more of their company's stock than they have bought. Specifically, they have bought $21,550.00 in company stock and sold $2,964,664.00 in company stock.

Percentage Held by Insiders

7.21% of the stock of Immunome is held by insiders.

Percentage Held by Institutions

44.58% of the stock of Immunome is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IMNM Stock Analysis - Frequently Asked Questions

How have IMNM shares performed this year?

Immunome's stock was trading at $21.48 at the beginning of 2026. Since then, IMNM shares have increased by 3.3% and is now trading at $22.19.

How were Immunome's earnings last quarter?

Immunome, Inc. (NASDAQ:IMNM) issued its quarterly earnings data on Tuesday, March, 3rd. The company reported ($0.75) EPS for the quarter, missing analysts' consensus estimates of ($0.65) by $0.10.

When did Immunome IPO?

Immunome (IMNM) raised $39 million in an initial public offering (IPO) on Thursday, October 1st 2020. The company issued 3,250,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Chardan served as the underwriters for the IPO.

Who are Immunome's major shareholders?

Immunome's top institutional investors include Principal Financial Group Inc. (1.22%), Bank of New York Mellon Corp (0.24%), SG Americas Securities LLC (0.03%) and Dimensional Fund Advisors LP (0.03%). Insiders that own company stock include Isaac Barchas, Clay B Siegall, Philip Wagenheim, Max Rosett, Philip Tsai, Bruce Turner, Jean Jacques Bienaime, Jack Higgins and Robert Lechleider.
View institutional ownership trends.

How do I buy shares of Immunome?

Shares of IMNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Immunome own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immunome investors own include NVIDIA (NVDA), Humana (HUM), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 3/03/2026
• Today: 5/07/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMNM
• CIK: 1472012
• Web: immunome.com
• Phone: 610-321-3700
• Fax: N/A
• Employees: 40
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Immunome: $33.45
• High Price Target: $40.00
• Low Price Target: $22.00
• Potential Upside/Downside: +50.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.91
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$212.39 million
• Net Margins: N/A
• Pretax Margin: -3,059.99%
• Return on Equity: -57.61%
• Return on Assets: -52.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.69
• Quick Ratio: 14.69

Sales & Book Value

• Annual Sales: $6.94 million
• Price / Sales: 362.11
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.75 per share
• Price / Book: 3.86

Miscellaneous

• Outstanding Shares: 113,250,000
• Free Float: 105,085,000
• Market Cap: $2.51 billion
• Optionable: Optionable
• Beta: 2.11